DYNE THERAPEUTICS INC

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

09 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

23 Sep 2024 07:56:28 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Key Leadership Appointments

03 Sep 2024 05:31:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

03 Sep 2024 05:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

29 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

12 Aug 2024 16:10:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

24 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

13 Jun 2024 15:40:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

30 May 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

28 May 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

21 May 2024 19:39:57 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

20 May 2024 15:01:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

20 May 2024 05:30:06 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

19 May 2024 07:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 May 2024 15:10:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

27 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

27 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces CEO Transition

25 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

13 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

05 Mar 2024 06:30:00 By Nasdaq GlobeNewswire